公司资料
DexCom, Inc. 股价、新闻与催化剂
- 股票代码:
- DXCM
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
86.23 USD (-0.07%)
收盘价
最后更新: 2026年10月1日
28.3B USD
市值
股价为何变动
截至 2026年10月1日，DXCM 股价变化不大，收于 $86.23。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Glucose Biosensing Company
Dexcom develops continuous glucose monitoring systems that help people measure and manage glucose without relying only on intermittent finger-stick tests. Its products serve people with diabetes as well as consumers seeking broader metabolic-health insights.
Prescription CGM Franchise
The Dexcom G7 platform provides real-time glucose readings, alerts, trend information, and connectivity to compatible mobile devices and insulin-delivery systems. The franchise is used across intensive insulin therapy, basal insulin, and expanding populations with type 2 diabetes.
Stelo Consumer Platform
Stelo is an over-the-counter glucose biosensor and app designed for adults who do not use insulin. It extends Dexcom into direct-to-consumer distribution and combines glucose data with food logging, behavioral insights, and AI-enabled interpretation.
Clinical Evidence and Market Expansion
Dexcom invests in randomized studies such as CONNECT to demonstrate the value of continuous glucose monitoring in less intensively treated populations. Evidence generation supports payer coverage, clinical guidelines, and adoption among primary-care clinicians and people with type 2 diabetes.
Connected Diabetes Ecosystem
The company integrates its sensors with insulin pumps, connected pens, digital health applications, and clinical data platforms. These partnerships make Dexcom's data a core component of automated insulin delivery and remote diabetes management.
未来催化剂
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。